期刊文献+

血清HE4浓度在妇科盆腔恶性肿瘤诊断中的应用 被引量:8

The Significance of HE4 Levels in the Diagnosis of Gynecological Pelvic Malignant Tumor
下载PDF
导出
摘要 目的:探讨人附睾蛋白4(HE4)&清含量在妇科盆腔肿物鉴别诊断中的价值。方法:检测132例妇女血清HE4水平,其中46例体检健康妇女作为正常对照组(n=46),86例盆腔肿物住院患者按术后病理结果分为良性病变组(n=56)和恶性病变组(n=30)。结果:正常对照组血清HE4范围是23.5~46.0pmol/L,均值为34.1±5.6pmol/L;艮性病变组血清HE4范围是30.1~58.9pmol/L,均值为39.1±7.2pmol/L;恶性病变组血清HF4范围是31.2—1430.0pmol/L,均值为248.7±364.5pmol/L,恶性病变组HE4水平明显高于其他两组,差异有统计学意义(P〈0.001)。HE4在51.6pmol/L时诊断指数最大(0.847),灵敏性和特异性分别为86.7%和98.0%,ROC曲线下面积0.935(95%CI:0.832-1.037,P=0.000)。HE4诊断盆腔恶性肿瘤的一致性检验Kappa值为0.867,/9=0.000。结论:血清HE4浓度测定是卵巢良、恶性肿瘤的鉴别诊断的良好指标。 Objective: To investigate the advantages of assessing the expression of human epididymis gene product 4 (HE4) in the differential diagnosis of gynecological pelvic tumor. Methods: We detected the level of serum HE4 in 132 women who were divided into the following three groups according to their postoperative pathology results: the normal control group (n=46), the benign group (n=56) and the malignant group (n=30). Results: The range of serum HE4 levels in the normal control group was 23.5-46.0 pmol/L with an average of 34.1±5.6 pmol/ L The range of serum HE4 levels in the benign group was 30.1-58.9pmo1/L with an average of 39.1±7.2 pmol/L. The range of serum HE4 levels in the malignant group was 31.2-1430.0 pmol/L, with an average of 248.7±364.5 pmol/L. The level of HE4 in the malignant group was significantly higher than that in the other two groups, with a significant difference (p=〈0.001). A serum HE4 level of 51.6 pmol/L had the most significant diagnostic index (0.847), with a sensitivity of 86.7% and a specificity of 98.0%. The ROC area under the curve was 0.935 (95% CI 0.832-1.037, P=0.000). Checking the Kappa value of HE4 in diagnosing pelvic cancer gave a consistency of 0.867 (P=-0.000). Conclusion: Serum level of HE4 protein is a good indicator for use in the differential diagnosis of benign and malignant ovarian tumors.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2009年第4期181-183,共3页 Chinese Journal of Clinical Oncology
基金 河北省科技厅科技研究与发展指导计划基金资助(编号:072761638)~~
关键词 人附睾蛋白4(HE4) 卵巢肿瘤 盆腔肿物 Human epididymis gene product 4 (HE4) Ovarian cancer Pelvic masses
  • 相关文献

参考文献11

  • 1杨国奋,李晓明,谢丹,朝葵,蔡鹏宇.卵巢癌组织中clusterin蛋白表达和细胞凋亡检测[J].中国肿瘤临床,2007,34(12):674-676. 被引量:17
  • 2黄啸,蔡树模,范建玄,李子庭.晚期卵巢上皮性癌的综合治疗和预后分析[J].中华妇产科杂志,2002,37(5):291-293. 被引量:45
  • 3曹泽毅.中华妇产科学[M].北京:人民卫生出版社,1999.2129.
  • 4Redman C, Bradgate MG, Rollason TP, et al. Cancer antigen CA125 in epithelial ovarian cancer: immunohistochemical expression before and after chemotherapy[J]. Eur j Cancer Clin Oncol, 1988, 24(8): 1381-1382.
  • 5Wang K, Gan L,Jeffery E, et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray[J]. Gene, 1999, 229(1-2): 101-108.
  • 6Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas[J]. Gene, 1999, 238(2): 375-385.
  • 7陈颖,赵雨杰,辛彦.cDNA芯片在卵巢癌早诊及临床病理分期中的初步应用探讨[J].中国肿瘤临床,2006,33(23):1338-1341. 被引量:7
  • 8Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues[J]. Mod Pathol, 2006, 19(6): 847-853.
  • 9Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinomaS. Cancer Res, 2003, 63(13): 3695-3700.
  • 10Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecol Oncol, 2008, 108(2): 402-408.

二级参考文献18

  • 1俞鸣,郝继辉,焦振山,史玉荣,郝希山,王庆生.卵巢上皮性癌BRCA1和p53基因表达的临床意义及相互关系研究[J].中国肿瘤临床,2005,32(1):18-20. 被引量:4
  • 2高颖,娄阁.库肯勃瘤中CD44v6﹑VEGF﹑MMP-2﹑MMP-9的表达及相关性研究[J].中国肿瘤临床,2005,32(24):1381-1385. 被引量:2
  • 3蒋林芳,谢丹,杨国奋,徐方平,肖柳珍.AIB1基因在卵巢癌中的扩增与蛋白表达及其临床意义[J].中国肿瘤临床,2006,33(10):559-561. 被引量:3
  • 4孙燕 周际昌.临床肿瘤内科手册(第3版)[M].北京:人民卫生出版社,1997.53-54.
  • 5Hough CD,Sherman-Baust CA,Pizer ES,et al.Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer[J].Cancer Res,2000,60(22):6281~6287
  • 6Trougakos IP,Gonos ES.Clusterin/apolipoprotein J in human aging and cancer[J].Int J Biochem Cell Biol,2002,34(11):1430~1448
  • 7Steinberg J,Oyasu R,Lang S,et al.Intracellular levels of SGP-2 (Clusterin)correlate with tumor grade in prostate cancer[J].Clin Cancer Res,1997,3(10):1707~1711
  • 8Miyake H,Gleave M,Kamidono S,et al.Overexpression of clusterin in transitiohal cell carcinoma of the bladder is related to disease progression and recurrence[J].Urology,2002,59(1):150~154
  • 9Xie D,Lau SH,Sham JS,et al.Up-regulated expression of cytoplasmic dusterin in human ovarian carcinoma[J].Cancer,2005,103(2):277~283
  • 10Yamasaki F,Tokunaga O,Sugimori H.Apoptotic index in ovarian carcinoma:correlation with clinicopathologic factors and prognosis[J].Gynecol Oncol,1997,66(3):439~448

共引文献3293

同被引文献45

  • 1王治国,王薇,李小鹏.测量不确定度及其在临床检验中应用[J].中国卫生统计,2005,22(2):85-86. 被引量:57
  • 2何军,韩辉(综述),郭爱华(审校).血清CA125水平临床意义的研究进展[J].新疆医科大学学报,2007,30(5):528-529. 被引量:12
  • 3Moss EL, Hollingworth J, Reynolds TM, The role of CA125 in clinical practice[J]. J C/in Pathol,2005,58(3) :308-312.
  • 4Drapkin R, yon Horsten HH, Lin Y,et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas[ J]. Cancer Res, 2005,65(6) :2162-2169.
  • 5Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma [ J ]. Cancer Res,2003,63 ( 13 ) :3695-3700.
  • 6Montagnana M, Lippi G, Ruzzenente O,et al. The utility of serum human epididymis protein 4 (HFA) in patients with a pelvic mass[J]. J Clin Lab Anal, 2009,23(5) :331-335.
  • 7Li J, Dowdy S, Tipton T, et al. HFA as a biomarker for ovarian and endometrial cancer management[ J]. Expert Rev Mol Diagn, 2009,9(6) :555-566.
  • 8Huhtinen K, Suvitie P, Hiissa J. Serum HFA concentration differentiates malignant ovarian turnouts from ovarian endometriotic cysts[ J]. Br J Cancer, 2009,101 (3) :548.
  • 9Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass [ J ]. Gyneeol Oneol, 2008,108 (2) : 402-408.
  • 10Shah CA, Lowe KA, Paley P,et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125 [ J]. Cancer Epidemiol Biomarkers Prey, 2009,18 ( 5 ) : 1365-1372.

引证文献8

二级引证文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部